multiple dose studies [Design Issues]

posted by Loky do – Egypt, 2024-03-04 11:27 (39 d 03:14 ago) – Posting: # 23892
Views: 719


I have a solifenacin succinate/tamsulosin HCl bioequivalence study, I will perform a multiple-dose study for tamsulosin modified release for Europe, I'm a little confused about the planned washout for this study as there are no enough public assessment reports for the combination, should I take in account the solifenacin washout period also or to design on tamsulosin only is enough (i.e one-week washout between 2 periods from last dose)

thanks in advance

Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,980 posts in 4,821 threads, 1,657 registered users;
33 visitors (0 registered, 33 guests [including 13 identified bots]).
Forum time: 15:42 CEST (Europe/Vienna)

Never, never, never use any software!
Never, never, never trust any computer!    Detlew Labes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz